ALDX Aldeyra Therapeutics Inc.

9.46
-0.03  -0%
Previous Close 9.49
Open 9.43
Price To Book 8.68
Market Cap 248272346
Shares 26,244,434
Volume 137,593
Short Ratio
Av. Daily Volume 258,119

SEC filingsSee all SEC filings

  1. 8-K - Current report 181197017
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181185131
  3. 8-K - Current report 181180453
  4. CT ORDER - Confidential treatment order 181107746
  5. 8-K - Current report 181094707

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 planned for 2019.
ADX-102
Dry eye syndrome
Phase 3 data due early 2019.
Reproxalap (ADX-102)
Allergic conjunctivitis
Phase 3 data due 2H 2019.
ADX-102
Noninfectious anterior uveitis
Phase 3 initial data due in 2H 2019.
ADX-102
Sjögren-Larsson Syndrome (SLS)
Phase 2 trial to be initiated in 2019.
ADX-1612 (ganetespib)
Mesothelioma

Latest News

  1. Edited Transcript of ALDX earnings conference call or presentation 14-Nov-18 1:00pm GMT
  2. Should You Be Concerned About Aldeyra Therapeutics Inc’s (NASDAQ:ALDX) Historical Volatility?
  3. Aldeyra Therapeutics to Participate at Citi's 2018 Global Healthcare Conference
  4. Aldeyra Therapeutics Announces Third Quarter 2018 Financial Results
  5. Recent Analysis Shows Freightcar America, Anworth Mortgage Asset, AMN Healthcare Services, Cenovus Energy, Dynex Capital, and Aldeyra Therapeutics Market Influences — Renewed Outlook, Key Drivers of Growth
  6. Aldeyra Therapeutics to Present at the 2018 Stifel Healthcare Conference
  7. Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third Quarter 2018 Financial Results
  8. Research Report Identifies Aldeyra Therapeutics, AAON, Douglas Dynamics, Insmed, Northern Oil and Gas, and SMART Global with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
  9. Mangrove Partners: Performance, AUM, and Holdings
  10. Aldeyra Therapeutics (ALDX) Looks Good: Stock Adds 7.5% in Session
  11. Aldeyra Therapeutics to Present at the 2018 Cantor Global Healthcare Conference
  12. Aldeyra Therapeutics, Inc. Announces Public Offering of Common Stock
  13. Aldeyra Surges on Positive Dry Eye Study Data on Reproxalap
  14. The Daily Biotech Pulse: Hologic Goes Shopping, Johnson & Johnson Snaps Ties With Geron
  15. Today’s Research Reports on Stocks to Watch: Aldeyra Therapeutics and Alexion Pharmaceuticals
  16. Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
  17. Aldeyra Therapeutics Stock Skyrockets on Dry Eye Study Results
  18. The Daily Biotech Pulse: Verastem's Chinese Duvelisib Licensing Deal, Aldeyra's Positive Dry Eye Disease Drug Trial
  19. Alderya's stock rockets after positive trial results of mesothelioma treatment
  20. Aldeyra Therapeutics Announces Positive Results from Phase 2b Dry Eye Disease Clinical Trial

SEC Filings

  1. 8-K - Current report 181197017
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181185131
  3. 8-K - Current report 181180453
  4. CT ORDER - Confidential treatment order 181107746
  5. 8-K - Current report 181094707
  6. 424B5 - Prospectus [Rule 424(b)(5)] 181094574
  7. 424B5 - Prospectus [Rule 424(b)(5)] 181088076
  8. 8-K - Current report 181086872
  9. 8-K - Current report 181084717
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 181005261